CIRCULARITY-SPONSORED RESEARCH CONDUCTED BY WORLD-CLASS EXPERTS
Title: New prospect of treatment of wound healing
- Researcher: Professor Puruhito
o Thoracic, cardiac and vascular surgery, medical faculty, Universitas Airlangga, Surabaya, Indonesia - Sample: Diabetic patients with ulcers identified as Wagner 1 to 3.
Most important findings:
- All diabetic foot ulcers evaluated during the study time period presented marked clinical improvements, and some patients gained total ulcer resolution.
Title: Complex treatment of complicated crural decollement injury in a diabetic patient
- Researchers: I. Gárgyán, Á. Csonka, K. Boa, E. Varga
o Department of Traumatology, University of Szeged, Hungary - Sample: Case presentation
Most important findings:
- A patient had a stage 4 ulcer with necrotic borders secondary to a car-accident-associated fracture with massive soft tissue contusion and crural decollement.
Results: The physician used the D’OXYVA® medical device as adjuvant therapy to save the patient’s limb from amputation and obtain complete ulcer resolution after 3 months of therapy.
Title: Transdermal delivery of carbon dioxide boosts microcirculation in subjects with and without diabetes
Researchers: Lee C. Rogers, D.P.M., Judy M. Muller-Delp, Ph.D., Topy A. Mudde, MSc.
- Sample: Healthy and diabetic patients
Most important findings:
- All of the flux parameters demonstrated marked improvement after the use of the D’OXYVA® device. The skin perfusion index increased after CO2 transdermal treatment. The diabetic participants demonstrated the most flux improvement after treatment, compared with healthy individuals. Both groups demonstrated improved blood pressure.
Title: Pilot study of D’OXYVA® transdermal gas delivery device in adult equines
Researchers: Dr. Karen Indreland, DVM
Sample: Healthy horses
Most important findings:
A D’OXYVA® device was used to provide high-concentration-CO2 water vapor, which increased microcirculation (flux) blood flow in the superficial skeletal muscle and skin of equines, compared with the control group.
Why can D’OXYVA® and its highly concentrated CO2 vapor improve general health care?
Judy M. Delp, Ph.D. professor of Biomedical Sciences in physiology and professor at the Florida State University, described D’OXYVA® as a simple commercially available device used to deliver transdermal CO2 that has shown remote vasodilation, which may be mediated through the release of a circulating humoral agent.**
CO2 improves general healthcare in several ways:
-
-
- It has natural anti-inflammatory characteristics.
-
-
-
- It increases blood flow through microcirculation, by arteriolar/venous dilatation.
-
-
-
- It produces a rightward shift in the O2 dissociation curve.
-
-
-
- It enhances oxygen delivery at the cellular level in the muscles, organs, brain, skin and other parts of the body.
-
-
-
- It is a fat-dissolving compound.
-
-
-
- It naturally sedates and calms the central nervous system.
-
-
-
- It can be used to reconstruct functionally closed capillaries.
-
-
-
- It can improve venous response.
-
-
-
- It improves blood-flow properties.
-
-
-
- It can be used to sedate the central nervous system.
-
Fill out the form below to receive a copy of D'OXYVA's outstanding clinical research results.
Latest Breakthroughs
The Blog.
Circularity Healthcare Announces Expansion with Global CRO of Series of Successful Pivotal Human Clinical Trials to Study Use of D’OXYVA® for Rapid, Economical and Noninvasive Home Treatment of Diabetic Foot Ulcers (DFU)
PASADENA, Calif., Feb. 1, 2021 5:31 AM PST (MORNINGSTAR) Addressing urgent and increased DFU problem related to pandemic lockdowns. Circularity Healthcare announced it had successfully executed a contract with the
Innovative Collaboration: The Cutting Edge of Medicine Goes “Behind The Scenes”
LOS ANGELES (PRWEB) DECEMBER 11, 2019 Circularity is partnering with Telly Award-Winning “Behind the Scenes” to provide regular, ongoing, high-quality content from leading experts in a variety of fields with an
Switch To D'OXYVA®.
The only gentle, rapid, and painless transdermal solution without breaking the layers of the skin.
D’OXYVA® (deoxyhemoglobin vasodilator) biotechnology provides an inexpensive, simple and effective method of mild to severe chronic wound care. Its fully noninvasive transdermal approach delivers a host of benefits including but not limited to significant blood flow in the microcirculation (perfusion index), oxygen saturation (SpO2), nutrients, nerve stimulation (parasympathetic), which together are crucial for the complete and painless wound healing process.
Get in touch to avail D’OXYVA® for rapid chronic wound treatment.
